Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

L. Paz-Ares, M. Dvorkin, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, MJ. Hochmair, M. Özgüroğlu, JH. Ji, O. Voitko, A. Poltoratskiy, S. Ponce, F. Verderame, L. Havel, I. Bondarenko, A. Kazarnowicz, G. Losonczy, NV. Conev, J....

. 2019 ; 394 (10212) : 1929-1939. [pub] 20191004

Language English Country Great Britain

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19044511
E-resources Online Full text

NLK ProQuest Central from 1992-01-04 to 3 months ago
Nursing & Allied Health Database (ProQuest) from 1992-01-04 to 3 months ago
Health & Medicine (ProQuest) from 1992-01-04 to 3 months ago
Family Health Database (ProQuest) from 1992-01-04 to 3 months ago
Psychology Database (ProQuest) from 1992-01-04 to 3 months ago
Health Management Database (ProQuest) from 1992-01-04 to 3 months ago
Public Health Database (ProQuest) from 1992-01-04 to 3 months ago

Links

PubMed 31590988
DOI 10.1016/s0140-6736(19)32222-6
Knihovny.cz E-resources

BACKGROUND: Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum-etoposide) in treatment-naive patients with ES-SCLC. METHODS: This randomised, open-label, phase 3 trial was done at 209 sites across 23 countries. Eligible patients were adults with untreated ES-SCLC, with WHO performance status 0 or 1 and measurable disease as per Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were randomly assigned (in a 1:1:1 ratio) to durvalumab plus platinum-etoposide; durvalumab plus tremelimumab plus platinum-etoposide; or platinum-etoposide alone. All drugs were administered intravenously. Platinum-etoposide consisted of etoposide 80-100 mg/m2 on days 1-3 of each cycle with investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle). Patients received up to four cycles of platinum-etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks in the immunotherapy groups and up to six cycles of platinum-etoposide every 3 weeks plus prophylactic cranial irradiation (investigator's discretion) in the platinum-etoposide group. The primary endpoint was overall survival in the intention-to-treat population. We report results for the durvalumab plus platinum-etoposide group versus the platinum-etoposide group from a planned interim analysis. Safety was assessed in all patients who received at least one dose of their assigned study treatment. This study is registered at ClinicalTrials.gov, NCT03043872, and is ongoing. FINDINGS: Patients were enrolled between March 27, 2017, and May 29, 2018. 268 patients were allocated to the durvalumab plus platinum-etoposide group and 269 to the platinum-etoposide group. Durvalumab plus platinum-etoposide was associated with a significant improvement in overall survival, with a hazard ratio of 0·73 (95% CI 0·59-0·91; p=0·0047]); median overall survival was 13·0 months (95% CI 11·5-14·8) in the durvalumab plus platinum-etoposide group versus 10·3 months (9·3-11·2) in the platinum-etoposide group, with 34% (26·9-41·0) versus 25% (18·4-31·6) of patients alive at 18 months. Any-cause adverse events of grade 3 or 4 occurred in 163 (62%) of 265 treated patients in the durvalumab plus platinum-etoposide group and 166 (62%) of 266 in the platinum-etoposide group; adverse events leading to death occurred in 13 (5%) and 15 (6%) patients. INTERPRETATION: First-line durvalumab plus platinum-etoposide significantly improved overall survival in patients with ES-SCLC versus a clinically relevant control group. Safety findings were consistent with the known safety profiles of all drugs received. FUNDING: AstraZeneca.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044511
003      
CZ-PrNML
005      
20200115092039.0
007      
ta
008      
200109s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(19)32222-6 $2 doi
035    __
$a (PubMed)31590988
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Paz-Ares, Luis $u Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain. Electronic address: lpazaresr@seom.org.
245    10
$a Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial / $c L. Paz-Ares, M. Dvorkin, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, MJ. Hochmair, M. Özgüroğlu, JH. Ji, O. Voitko, A. Poltoratskiy, S. Ponce, F. Verderame, L. Havel, I. Bondarenko, A. Kazarnowicz, G. Losonczy, NV. Conev, J. Armstrong, N. Byrne, N. Shire, H. Jiang, JW. Goldman, CASPIAN investigators,
520    9_
$a BACKGROUND: Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum-etoposide) in treatment-naive patients with ES-SCLC. METHODS: This randomised, open-label, phase 3 trial was done at 209 sites across 23 countries. Eligible patients were adults with untreated ES-SCLC, with WHO performance status 0 or 1 and measurable disease as per Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were randomly assigned (in a 1:1:1 ratio) to durvalumab plus platinum-etoposide; durvalumab plus tremelimumab plus platinum-etoposide; or platinum-etoposide alone. All drugs were administered intravenously. Platinum-etoposide consisted of etoposide 80-100 mg/m2 on days 1-3 of each cycle with investigator's choice of either carboplatin area under the curve 5-6 mg/mL per min or cisplatin 75-80 mg/m2 (administered on day 1 of each cycle). Patients received up to four cycles of platinum-etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks in the immunotherapy groups and up to six cycles of platinum-etoposide every 3 weeks plus prophylactic cranial irradiation (investigator's discretion) in the platinum-etoposide group. The primary endpoint was overall survival in the intention-to-treat population. We report results for the durvalumab plus platinum-etoposide group versus the platinum-etoposide group from a planned interim analysis. Safety was assessed in all patients who received at least one dose of their assigned study treatment. This study is registered at ClinicalTrials.gov, NCT03043872, and is ongoing. FINDINGS: Patients were enrolled between March 27, 2017, and May 29, 2018. 268 patients were allocated to the durvalumab plus platinum-etoposide group and 269 to the platinum-etoposide group. Durvalumab plus platinum-etoposide was associated with a significant improvement in overall survival, with a hazard ratio of 0·73 (95% CI 0·59-0·91; p=0·0047]); median overall survival was 13·0 months (95% CI 11·5-14·8) in the durvalumab plus platinum-etoposide group versus 10·3 months (9·3-11·2) in the platinum-etoposide group, with 34% (26·9-41·0) versus 25% (18·4-31·6) of patients alive at 18 months. Any-cause adverse events of grade 3 or 4 occurred in 163 (62%) of 265 treated patients in the durvalumab plus platinum-etoposide group and 166 (62%) of 266 in the platinum-etoposide group; adverse events leading to death occurred in 13 (5%) and 15 (6%) patients. INTERPRETATION: First-line durvalumab plus platinum-etoposide significantly improved overall survival in patients with ES-SCLC versus a clinically relevant control group. Safety findings were consistent with the known safety profiles of all drugs received. FUNDING: AstraZeneca.
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D000911
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $7 D061067
650    _2
$a protinádorové látky imunologicky aktivní $x aplikace a dávkování $x škodlivé účinky $7 D000074322
650    _2
$a fytogenní protinádorové látky $x aplikace a dávkování $7 D000972
650    _2
$a protokoly protinádorové kombinované chemoterapie $7 D000971
650    _2
$a karboplatina $x aplikace a dávkování $x škodlivé účinky $7 D016190
650    _2
$a cisplatina $x aplikace a dávkování $x škodlivé účinky $7 D002945
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a etoposid $x aplikace a dávkování $x škodlivé účinky $7 D005047
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x farmakoterapie $x mortalita $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a malobuněčný karcinom plic $x farmakoterapie $x mortalita $7 D055752
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dvorkin, Mikhail $u BHI of Omsk Region Clinical Oncology Dispensary, Omsk, Russia.
700    1_
$a Chen, Yuanbin $u Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, USA.
700    1_
$a Reinmuth, Niels $u Asklepios Lung Clinic, Munich-Gauting, Germany.
700    1_
$a Hotta, Katsuyuki $u Okayama University Hospital, Okayama, Japan.
700    1_
$a Trukhin, Dmytro $u Odessa National Medical University, Odessa, Ukraine.
700    1_
$a Statsenko, Galina $u Omsk Regional Cancer Center, Omsk, Russia.
700    1_
$a Hochmair, Maximilian J $u Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Krankenhaus Nord, Vienna, Austria.
700    1_
$a Özgüroğlu, Mustafa $u Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey.
700    1_
$a Ji, Jun Ho $u Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
700    1_
$a Voitko, Oleksandr $u Kyiv City Clinical Oncological Centre, Kiev, Ukraine.
700    1_
$a Poltoratskiy, Artem $u Petrov Research Institute of Oncology, St Petersburg, Russia.
700    1_
$a Ponce, Santiago $u Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain.
700    1_
$a Verderame, Francesco $u AO Ospedali Riuniti PO Vincenzo Cervello, Palermo, Italy.
700    1_
$a Havel, Libor $u Thomayer Hospital, First Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Bondarenko, Igor $u Dnipropetrovsk Medical Academy, Dnipro, Ukraine.
700    1_
$a Kazarnowicz, Andrzej $u Tuberculosis and Lung Disease Hospital, Olsztyn, Poland.
700    1_
$a Losonczy, György $u Semmelweis University, Budapest, Hungary.
700    1_
$a Conev, Nikolay V $u Clinic of Medical Oncology, UMHAT St Marina, Varna, Bulgaria.
700    1_
$a Armstrong, Jon $u AstraZeneca, Cambridge, UK.
700    1_
$a Byrne, Natalie $u AstraZeneca, Cambridge, UK.
700    1_
$a Shire, Norah $u AstraZeneca, Gaithersburg, MD, USA.
700    1_
$a Jiang, Haiyi $u AstraZeneca, Gaithersburg, MD, USA.
700    1_
$a Goldman, Jonathan W $u David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
710    2_
$a CASPIAN investigators
773    0_
$w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 394, č. 10212 (2019), s. 1929-1939
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31590988 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200115092413 $b ABA008
999    __
$a ok $b bmc $g 1482780 $s 1083184
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 394 $c 10212 $d 1929-1939 $e 20191004 $i 1474-547X $m Lancet $n Lancet $x MED00010161
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Archiving options